Latest Amgen Stories
Romosozumab Currently in Phase 3 Clinical Development, Pivotal Data Expected in 2016 THOUSAND OAKS, Calif. and BRUSSELS, Sept.
Analysis From SHIFT Study Shows Ivabradine Reduced Cardiovascular Death or Hospitalization for Worsening Heart Failure Independent of Baseline Blood Pressure With Similar Safety Profile Across Groups THOUSAND
Data Include Eight Year Analyses of Bone Mineral Density Results for Prolia® (Denosumab) and Further Evidence for Significant Bone-Building With Romosozumab THOUSAND OAKS, Calif., Sept.
THOUSAND OAKS, Calif., Sept. 5, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept.
First Marketing Authorization Application for an Oncolytic Immunotherapy in the European Union THOUSAND OAKS, Calif., Sept.
Represents First Marketing Authorization Application in the European Union for a PCSK9 Inhibitor THOUSAND OAKS, Calif., Sept.
Represents First BLA Submission for a PCSK9 Inhibitor THOUSAND OAKS, Calif., Aug.
AllMed webinar provides in-depth review of the latest standard of care for the use of ESAs in the treatment of Chronic Kidney Disease. Portland, OR (PRWEB) August
THOUSAND OAKS, Calif., Aug. 27, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S.
IRVINE, Calif., Aug. 25, 2014 /PRNewswire/ -- Western Digital Corp.
- An imitative word; an onomatopoetic word.